10 Trending AI Stocks on Latest News and Ratings

Page 3 of 10

8. ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA)

Number of Hedge Fund Holders: 1

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) is a biotechnology company leveraging multi-omics modeling and complex artificial intelligence to discover and develop therapeutic antibodies. On January 17, the company announced the launch of its AI-powered drug development pipeline designed to revolutionize how new treatments are discovered and optimized. IPA is leading the pack in AI-powered drug discovery, with the BioStrand pipeline transforming drug discovery and offering unmatched speed, precision, and transparency. Unlike traditional drug discovery methods that rely on outdated frameworks, IPA’s approach rebuilds processes from scratch. This has led to the creation of LENSai, IPA’s proprietary AI platform. The LENSai™ platform enables AI-driven drug discovery and organizing complex biological data for speeding up discoveries and eliminating inefficiencies. Powered by LENSai’s, the IPA pipeline enables AI-enhanced therapies that in turn ensure the delivery of treatments is groundbreaking, highly effective, and reliable.

“Our AI-powered pipeline represents a major leap forward for IPA. By harnessing AI and rethinking drug discovery from the ground up, we are not just improving the process—we are fundamentally changing what’s possible. This pipeline lays the foundation for groundbreaking advancements in therapeutic development, embodying our vision of innovation driven by clarity, precision, and purpose”.

-Dr. Jennifer Bath, CEO of ImmunoPrecise Antibodies.

Page 3 of 10